We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXST icon
76
RxSight
RXST
$252M
$14.4K 0.27%
1,202,833
-180,667
-13% -$2.48M
JBIO
77
Jade Biosciences
JBIO
$1.17B
$13.2K 0.24%
22,714
+9,040
+66% +$6.03M
PASG icon
78
Passage Bio
PASG
$14.2M
$11.2K 0.21%
446,600
– –
MIRM icon
79
Mirum Pharmaceuticals
MIRM
$6.63B
$11K 0.2%
521,891
+242,391
+87% +$5.84M
IMA
80
ImageneBio Inc
IMA
$64.8M
$10.4K 0.19%
244,495
– –
CINC
81
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$10.3K 0.19%
+314,202
New +$8.88M
ELVN icon
82
Enliven Therapeutics
ELVN
$3.78B
$10K 0.19%
1,096,642
– –
FUSN
83
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.71K 0.18%
3,224,770
– –
IRON icon
84
Disc Medicine
IRON
$2.8B
$9.55K 0.18%
194,207
– –
MREO
85
Mereo BioPharma
MREO
$50.2M
$9.13K 0.17%
10,605,522
+8,004,054
+308% +$9.79M
XFOR icon
86
X4 Pharmaceuticals
XFOR
$374M
$8.6K 0.16%
167,561
+121,766
+266% +$4.21M
CGEM icon
87
Cullinan Oncology
CGEM
$1.03B
$8.17K 0.15%
637,287
-33,500
-5% -$451K
RCUS icon
88
Arcus Biosciences
RCUS
$3.3B
$7.93K 0.15%
+303,000
New +$8.01M
VTYX
89
DELISTED
Ventyx Biosciences
VTYX
$7.86K 0.15%
225,000
-1,064,280
-83% -$23.6M
DMRA
90
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.79B
$7.73K 0.14%
163,637
– –
EYPT icon
91
EyePoint Inc
EYPT
$994M
$7.68K 0.14%
970,860
+756,760
+353% +$7.03M
NXTC icon
92
NextCure
NXTC
$21.4M
$7.46K 0.14%
225,918
– –
LUNG icon
93
Pulmonx
LUNG
$52.4M
$7.25K 0.13%
435,000
– –
JNCE
94
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$6.85K 0.13%
2,928,900
– –
ORIC icon
95
Oric Pharmaceuticals
ORIC
$1.17B
$6.68K 0.12%
2,087,568
– –
CMMB
96
Chemomab Therapeutics
CMMB
$11.4M
$6.42K 0.12%
644,544
– –
XBI icon
97
State Street SPDR S&P Biotech ETF
XBI
$10B
$6.06K 0.11%
76,400
-35,400
-32% -$2.98M
PCVX icon
98
CALL
Vaxcyte
PCVX
$7.62B
$6K 0.11%
+250,000
New +$6.34M
SYBX
99
DELISTED
Synlogic
SYBX
$5.73K 0.11%
402,000
– –
CRVS icon
100
Corvus Pharmaceuticals
CRVS
$1.1B
$5.68K 0.11%
6,943,654
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.